Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Carisma Therapeutics Inc. buy melinda

Start price
€34.10
21.05.19 / 50%
Target price
€45.10
21.08.20
Performance (%)
-45.50%
End price
€18.58
21.08.20
Summary
This prediction ended on 21.08.20 with a price of €18.58. The BUY prediction by melinda for Carisma Therapeutics Inc. performed very badly with a performance of -45.50%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Carisma Therapeutics Inc. -1.651% -1.651% -86.824% -96.753%
iShares Core DAX® -0.992% -3.231% 11.661% 16.545%
iShares Nasdaq 100 -0.225% -3.339% 36.491% 43.334%
iShares Nikkei 225® -0.736% -7.859% 18.597% 4.253%
iShares S&P 500 -0.509% -2.979% 26.341% 40.911%

According to melinda what are the pros and cons of Carisma Therapeutics Inc. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Sesen Bio Inc diskutieren
Prediction Buy
Perf. (%) -45.50%
Target price 2.255
Change
Ends at 21.08.20

Secteur Recherche biotechnologique et médicale Agenda 13/05 Publication de résultats

Logo Sesen Bio Inc
Sesen Bio, Inc, anciennement Eleven Biotherapeutics, Inc, une société clinique en phase terminale qui fournit une plate-forme de thérapie protéique ciblée (TPT). Société se concentrant sur le développement des anticorps-médicaments conjugués (ADC) pour le traitement du cancer. Son portefeuille de produits comprend Vicinium, Vicinium en combinaison avec un inhibiteur de contrôle de contrôle, durvalumab et VB6-845d. Le programe principal de la Société, Vicinium, ainsi que la poursuite de la phase III de développement du traitement du cancer de la vessie non invasive et non musculaire (NMIBC).Les cibles antigènes de la molécule d'adhésion des cellules épithéliales (EpCAM) dans la cellule tumorale pour libérer une cytotoxine puissante, les exotoxines A de Pseudomonas (ETA), directement aux cellules cancéreuses.


Nombre d'employés

: 17 personnes.

In the thread Trading Sesen Bio Inc
Prediction Buy
Perf. (%) -45.50%
Target price 2.255
Change
Ends at 21.08.20

Buy beendet

Stopped prediction by melinda for Carisma Therapeutics Inc.

buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€16.58
16.10.21
-
16.10.22
22.56%
24.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.55
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.55
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.55
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€15.44
12.10.21
-
12.10.22
7.38%
16.10.21

Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€73.80
17.06.21
€50.00
17.06.22
-66.50%
17.08.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€18.58
21.08.20
€30.00
04.11.21
297.12%
17.06.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€22.73
05.05.19
€39.69
20.05.19
34.13%
20.05.19

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€26.34
31.10.18
€31.57
07.11.18
6.16%
07.11.18

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€13.35
19.11.17
€21.65
03.01.18
16.91%
03.01.18

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€47.45
10.07.16
€54.12
25.07.16
20.50%
25.07.16

Could be worthwhile Investment >10% per year